Effect of orlistat, a novel anti-obesity agent, on the pharmacokinetics and pharmacodynamics of pravastatin in patients with mild hypercholesterolaemia

Clinical Drug Investigation

Volumn 17, Issue 3, 1999, Pages 217-223

  Oo, Charles Y ^a   Akbari, Bardia ^a   Lee, Steve ^a   Nichols, Gary ^a   Hellmann, Christopher P ^a  

^a HOFFMANN LA ROCHE INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; TETRAHYDROLIPSTATIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFECT; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERCHOLESTEROLEMIA; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0033009311     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-199917030-00006     Document Type: Article

References (22)

1. Zhi J, Melia AT, Gierciolini R, et al. Retrospective population-based analysis of the dose-response (fecal fat exerction) relationship of orlistat in normal and obese volunteers. Clin Pharmacol Ther 1994; 56: 82-5
2. Van Gaal LF, Broom JI, Enzi G, et al. Efficacy and tolerability of orlistat in the treatment of obesity: a 6-month dose-ranging study. Eur J Clin Pharmacol 1998; 45: 125-32
3. Sjöström L, Rissanen A, Andersen T, et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet 1998; 352: 167-72
4. Davidson MH, Hauptman J, DiGirolamo M, et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat. JAMA 1998; 281: 235-42
5. Guercíolini R. Mode of action of orlistat. Int J Obes 1997; 21 Suppl. 3: S12-23
6. McTavish D, Sorkin EM. Pravastatin: a review of its pharmacology and therapeutic potential in hypercholesterolaemia. Drugs 1991; 41: 65-89
7. Schwartzkopff W, Bimmermann A, Schleicher J. Comparison of the efficacy of pravastatin and cholestyramine in hypercholesterolaemic patients. Arzneimittelforschung 1990; 40: 1322-7
8. Crepaldi G, Baggio G, Arca M, et al. Pravastatin vs gemfibrozil in the treatment of primary hypercholesterolaemia. The Italian Multicenter Pravastatin study I. Arch Intern Med 1991; 151: 146-52
9. Lovastatin Pravastatin Study Group. A multicenter comparative trial of lovastatin and pravastatin in the treatment of hypercholesterolaemia. Am J Cardiol 1993; 77: 810-5
10. Jacolot B, Benghozi R, Pfister P, et al. Comparison of fluvastatin versus pravastatin treatment of primary hypercholesterolaemia. Am J Cardiol 1995; 76: 54A-60A
11. Weir MR, Berger ML, Weeks ML, et al. Comparison of the effects on quality of life and of the efficacy and tolerability of lovastatin versus pravastatin. Am J Cardiol 1996; 77: 475-9
12. Singvhi SM, Pan HY, Morrison RA, et al. Disposition of pravastatin sodium, a tissue selective HMG-CoA reductase inhibitor, in healthy subjects. Br J Clin Pharmacol 1990; 29: 239-43
13. Denke MA, Sempos CT, Grundy SM. Excess body weight. An underrecognized contributor to high blood cholesterol levels in white American men. Arch Intern Med 1993; 153: 1093-103
14. Denke MA, Sempos CT, Grundy SM. Excess body weight. An underrecongnized contributor to dyslipidemia in white American women. Arch Intern Med 1994; 154: 401-10
15. Triscari J, Pan HY, DeVault A, et al. Comparative bioavailability of pravastatin following morning and evening dosing. Clin Pharmacol Ther 1991; 49: 178
16. Hunninghake DB, Mellies MJ, Goldberg AC, et al. Efficacy and safety of pravastatin in patients with primary hypercholesterolaemia JJ. Once-daily versus twice-daily dosing. Atherosclerosis 1990; 85: 219-27
17. Illingworth DR. Clinical implications of new drugs for lowering plasma cholesterol concentrations. Drugs 1991; 41: 151-60
18. Pan HY, DeVault AR, Swites BJ, et al. Pharmacokinetics and pharmacodynamics of pravastatin alone and with cholestyramine in hypercholesterolaemia. Clin Pharmacol Ther 1990; 48: 201-7
19. Pan HY, DeVault AR, Brescia D, et al. Effect of food on pravastatin pharmacokinetics and pharmacodynamics. Int J Clin Pharmacol Ther Toxicol 1993; 31: 291-4
20. Beattie DE, Güzelhan C, Jonkman JHG, et al. Open, parallel group interaction study of Ro-18-0647 on the pharmacokinetics and pharmacodynamics of pravastatin in hospitalized healthy volunteers. Hoffman-La Roche Research No. B-162 079 (data on file)
21. Zielonka J. An oral single rising high dose tolerance study of pravastatin in healthy subjects. Bristol-Myers Squibb Final Study Report: Protocol CV123-162 (data on file)
22. Pan HY, DeVault AR, Wang-Iverson D. Comparative pharmacokinetics and pharmaendynamics of pravastatin and lovastatin. J Clin Pharmacol 1990; 30: 1128-35